Catalyst Pharmaceuticals, Inc. Stock price

Equities

CPRX

US14888U1016

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
15.94 USD -2.03% Intraday chart for Catalyst Pharmaceuticals, Inc. -4.09% -5.18%
Sales 2024 * 464M Sales 2025 * 553M Capitalization 1.88B
Net income 2024 * 138M Net income 2025 * 186M EV / Sales 2024 * 3.06 x
Net cash position 2024 * 459M Net cash position 2025 * 682M EV / Sales 2025 * 2.16 x
P/E ratio 2024 *
13.7 x
P/E ratio 2025 *
10.4 x
Employees 167
Yield 2024 *
-
Yield 2025 *
-
Free-Float 93.59%
More Fundamentals * Assessed data
Dynamic Chart
Catalyst Pharmaceuticals Insider Sold Shares Worth $411,000, According to a Recent SEC Filing MT
Citigroup Starts Coverage on Catalyst Pharmaceuticals With Buy Rating, $27 Price Target MT
Santhera's Partner Catalyst Pharmaceuticals Launches AGAMREE(R) (Vamorolone) in the United States DJ
Catalyst Pharmaceuticals' Agamree Now Available in US to Treat Duchenne Muscular Dystrophy MT
Catalyst Pharmaceuticals Announces Agamree® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy CI
Transcript : Catalyst Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 01:35 PM
Catalyst Pharmaceuticals Receives Buy Rating From BofA on Track Record for License, Acquisition Deals MT
BofA Securities Initiates Catalyst Pharmaceuticals With Buy Rating, Price Target is $23 MT
Cantor Fitzgerald Raises Catalyst Pharmaceuticals' Price Target to $34 From $27, Maintains Overweight Rating MT
Transcript : Catalyst Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 29, 2024
Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024 CI
Catalyst Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Catalyst Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Catalyst Pharmaceuticals Seeks Acquisitions CI
Catalyst Pharmaceuticals Raises $140.1 Million From Share Offering MT
More news
1 day-2.03%
1 week-5.74%
Current month-0.56%
1 month+11.08%
3 months-7.81%
6 months+30.98%
Current year-5.18%
More quotes
1 week
15.67
Extreme 15.6701
16.67
1 month
15.28
Extreme 15.28
17.50
Current year
13.12
Extreme 13.1161
17.50
1 year
11.09
Extreme 11.09
18.22
3 years
4.16
Extreme 4.16
22.11
5 years
2.23
Extreme 2.232
22.11
10 years
0.51
Extreme 0.51
22.11
More quotes
Managers TitleAgeSince
Founder 77 01-12-31
Chief Executive Officer 62 15-02-18
Director of Finance/CFO 53 Dec. 31
Members of the board TitleAgeSince
Founder 77 01-12-31
Director/Board Member 78 15-02-18
Director/Board Member 60 02-09-30
More insiders
Date Price Change Volume
24-03-28 15.94 -2.03% 1,172,167
24-03-27 16.27 +3.30% 1,471,658
24-03-26 15.75 -0.69% 828,267
24-03-25 15.86 +0.83% 1,085,212
24-03-22 15.73 -5.35% 948,460

Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT

More quotes
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for children ages six to seventeen. The Company is also marketing FYCOMPA (perampanel) CIII as a prescription medication used alone or with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. Its portfolio also includes AGAMREE (vamorolone) an oral suspension 40 mg/ml for the treatment of Duchenne Muscular Dystrophy (DMD). The vamorolone is a corticosteroid treatment for patients suffering from DMD.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
15.94 USD
Average target price
26.86 USD
Spread / Average Target
+68.49%
Consensus
  1. Stock
  2. Equities
  3. Stock Catalyst Pharmaceuticals, Inc. - Nasdaq